Analysis of the Pseudomonas aeruginosa biofilm in the respiratory samples of cystic fibrosis patients

ISRCTN ISRCTN75391385
DOI https://doi.org/10.1186/ISRCTN75391385
Secondary identifying numbers BUN14320095387
Submission date
21/12/2012
Registration date
06/02/2013
Last edited
22/03/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Cystic fibrosis (CF) is an inherited disease that affects the internal organs, mainly the lungs and digestive system, by forming thick mucus plugs. Chronic pulmonary infections by the bacteria Pseudomonas aeruginosa (P. aeruginosa) are the main cause of mortality in CF patients. The specific biofilm mode of growth of P. aeruginosa in the CF-mucus enables this bacterium to escape the host immune system and currently available anti-microbial therapies and airway clearance techniques. Standard airway clearance techniques consist of autogenic drainage. A new technique is intrapulmonary percussive ventilation (IPV), in which chest physical therapy is administered to the airways by a pneumatic device that delivers percussive bursts into the lungs in certain frequencies (100-300, up to 900bpm). Research at the Belgian Nuclear Research Centre (SCK•CEN) showed that cultivation in a low fluid shear environment induced a P. aeruginosa biofilm phenotype similar to that in CF, while cultivation in a higher fluid shear did not support development of this CF phenotype. The main goal of this study is to investigate the influence of fluid shear on the P. aeruginosa biofilm in CF patients using IPV.

Who can participate?
Patients with CF (age greater than 6 years) who are hospitalised 3 to 4 times a year during 10 days or routine IV antibiotic treatment. Patients must be able to produce sputum. We will compare the patients who are infected with Pseudomonas aeruginosa (patient group), to those who are not infected (control group).

What does the study involve?
For each study participant, three different physiotherapy regimens will be tested during three different hospitalisation periods: autogenous drainage, IPV low frequency (200 bpm) and IPV high frequency (400 bpm). In the patient group we will analyse sputum samples for P. aeruginosa characteristics before and after the different physiotherapy regimens. This study will be performed blind which means that the researcher who analyses the samples in the lab will not be informed of the therapeutic group to which the patient belongs.

What are the possible benefits and risks of participating?
All treatments adopted during this study are routinely used by CF patients and have been proven to be safe. Consequently, this study does not involve any risk for the patient. New insights gained from this study will improve the understanding of bacterial behaviour following exposure to high shear treatment in vivo and will be applied to a purposive adaptation of the current treatment of cystic fibrosis patients.

Where is the study run from?
The CF reference centre at the University Hospital in Brussels (UZ Brussel), Belgium

When is study starting and how long is it expected to run for?
Patient recruitment started in January 2012 and the study will run until January 2014

Who is funding the study?
Belgian Cystic Fibrosis Association (BCFA) (Belgium)

Who is the main contact?
Dr J. Willekens
julie.willekens@uzbrussel.be

Contact information

Dr Julie Willekens
Scientific

Laarbeeklaan 101
Jette
1090
Belgium

Email Julie.Willekens@uzbrussel.be

Study information

Study designRandomised controlled single-blind cross-over trial
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleEffect of intrapulmonary percussive ventilation on Pseudomonas aeruginosa biofilm formation and virulence
Study objectivesAssuming that the lung mucus in cystic fibrosis (CF) patients is characterized by low fluid shear (as the main shear-causing factor, mucociliary clearance, is absent), we want to investigate the impact of increased fluid shear on P. aeruginosa growth features and virulence in vivo. For this purpose, we want to use intrapulmonary percussive ventilation (IPV) as this presumably increases fluid shear in the lungs.
Ethics approval(s)Medical Ethics Committee UZ Brussel, 01/12/2011, ref: 2009/004
Health condition(s) or problem(s) studiedCystic fibrosis / Pseudomonas aeruginosa biofilm / Intrapulmonary Percussive Ventilation (IPV)
InterventionThree different physiotherapy regimens (each patient will have all 3 regimens with a 3-month interval):
1. Autogenous drainage
2. IPV low frequency (200 bpm)
3. IPV high frequency (400 bpm)
Intervention typeProcedure/Surgery
Primary outcome measureAnalysis of P. aeruginosa abundance, physiology, virulence factors and gene expression on day 1, day 4 and day 10 of each hospitalisation
Secondary outcome measuresLung function values [Forced expiratory volume in the first one second (FEV1) and forced vital capacity (FVC)] on day 1 and day 10 of each hospitalisation
Overall study start date01/01/2012
Completion date01/01/2014

Eligibility

Participant type(s)Patient
Age groupMixed
SexBoth
Target number of participants10
Key inclusion criteria1. CF patients (diagnosis confirmed by sweat test)
2. Age greater than 6 years, upper age limit 60 years
3. Hospitalisation 3 to 4 times a year for routine intravenous (IV) antibiotic treatment
4. Clinically stable at time of study entry
Key exclusion criteria1. Lung transplantation
2. Massive hemoptysis
3. Pneumothorax
4. Pregnancy
5. Non-invasive and invasive ventilation
Date of first enrolment01/01/2012
Date of final enrolment01/01/2014

Locations

Countries of recruitment

  • Belgium

Study participating centre

Laarbeeklaan 101
Jette
1090
Belgium

Sponsor information

Belgian Cystic Fibrosis Association (BCFA) (Belgium)
Charity

Avenue J. Borlé 12
Brussel
1160
Belgium

Website http://www.muco.be

Funders

Funder type

Charity

Belgian Cystic Fibrosis Association (BCFA) (Belgium)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/06/2018 Yes No

Editorial Notes

22/03/2018: Publication reference added.